Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: A case-matched study in patients with lymphoproliferative malignancies

Annals of Hematology

Volumn 88, Issue 7, 2009, Pages 673-680

  Putkonen, Mervi ^a   Rauhala, Auvo ^b   Pelliniemi, Tarja Terttu ^a   Remes, Kari ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

Autologous stem cell transplant; Filgrastim; Lymphoproliferative disease; Mobilization; Pegfilgrastim

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; AUTOGRAFT; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CELL COUNT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; LEUKAPHERESIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEM CELL MOBILIZATION;

ADULT; AGED; ANTIGENS, CD34; CELL COUNT; DRUG EVALUATION; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKAPHERESIS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 67349128296     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0675-5     Document Type: Article

References (24)

1. Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM (1989) Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 74:1905-1914
2. Alegre A, Tomas JF, Martinez-Chamorro C, Gil-Fernandez JJ, Fernandez-Villalta MJ, Arranz R, Diaz MA, Granada A, Bernardo MR, Escudero A, Lopez-Lorenzo JL, Fernandez-Ranada JM (1997) Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: High-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 20:211-217 doi: 10.1038/sj.bmt.1700867
3. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A et al (1998) Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 16:1547-1553
4. Curran MP, Goa KL (2002) Pegfilgrastim. Drugs 62:1207-1213 doi: 10.2165/ 00003495-200262080-00012
5. Zamboni WC (2003) Pharmacokinetics of pegfilgrastim. Pharmacotherapy 23:9S-14S doi: 10.1592/phco.23.9.9S.32888
6. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J et al (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21:514-519 doi: 10.1200/JCO.2003.03.040
7. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ (2003) A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep 10:715-724
8. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-35 doi: 10.1093/ annonc/mdg019
9. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P et al (1999) A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27:1724-1734 doi: 10.1016/S0301-472X(99)00112-5
10. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B et al (2005) Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 35:33-36 doi: 10.1038/ sj.bmt.1704702
11. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR et al (2005) Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 90:225-231
12. Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Barate C et al (2006) Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplant 38:413-416 doi: 10.1038/sj.bmt.1705459
13. Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP et al (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 46:180-185 doi: 10.1111/j.1537-2995.2006.00699.x
14. Remes K, Matinlauri I, Grenman S, Itala M, Kauppila M, Pelliniemi TT et al (1997) Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery. J Hematother 6:13-19
15. Johnsen HE (1995) Report from a Nordic workshop on CD34+ cell analysis: technical recommendations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. Nordic Myeloma Study Group Laboratories. J Hematother 4:21-28
16. Kroschinsky F, Holig K, Poppe-Thiede K, Zimmer K, Ordemann R, Blechschmidt M et al (2005) Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 90:1665-1671
17. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731 doi: 10.1200/JCO.20.3.727
18. Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL et al (2005) Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: Phase II study. Bone Marrow Transplant 35:1165-1169 doi: 10.1038/sj.bmt.1704994
19. Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P (2005) Fixed-dose single administration of pegfilgrastim vs daily filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 35:889-893 doi: 10.1038/sj.bmt.1704927
20. Kroschinsky F, Hoelig K, Platzbecker U, Schleyer E, Ordeman R, Haack A (2004) Single-dose pegfilgrastim after chemotherapy is highly effective in enhancing the mobilization of autologous CD34+PBSC in patients with lymphoid malignancies and solid tumors. Blood 104:788a (abstract 2922)
21. Hosing C, Qazilbash M, Kebriaei P, Giralt S, Davis M, Popat U et al (2006) Fixed-dose single agent pegfilgrastim for peripheral blood prognitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133:533-537 doi: 10.1111/j.1365-2141.2006.06054.x
22. Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J, Seeger T, Zeller LWJ, Moehler T, Ho AD, Goldschmidt H (2007) Efficient mobilization of peripheral blood stem cell following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 39:743-750 doi: 10.1038/sj.bmt.1705675
23. Beveridge RA, Rifkin RM, Moleski RJ, Milkovich G, Reitan JF, Paivanas TA et al (2003) Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy 23:101S-109S doi: 10.1592/ phco.23.16.101S.31971
24. Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T et al (2003) Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 3:391-398